SGLT2 inhibitors are currently a standard of care in HFpEF following the results of EMPEROR-Preserved and DELIVER trials, which demonstrated significant reductions in heart failure hospitalizations across the spectrum of ejection fraction [37,39]. This evidence concerns the gene SLC5A2 and heart failure.